Company intelligence / Profile preview

Concert Pharmaceuticals

Lexington, Massachusetts, United Statesticketmaster.com ↗

Ownership: Private
Employees: ~100
Development stage: Commercial

Overview

Concert’s lead asset, deuruxolitinib, an oral JAK1/2 inhibitor for moderate to severe alopecia areata, completed two positive Phase 3 trials. The company planned to submit a New Drug Application in the first half of 2023. Two long-term extension studies were ongoing at the time of acquisition.

Therapeutic areas: Dermatology
Modalities: Small moleculeDeuterated small molecule
Industry: Biotech

Partnerships

GlaxoSmithKline partnership on deuterium-modified drugs in earlier yearsVarious clinical research collaborations over company history

Beyond the preview

Go deeper on Concert Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Concert Pharmaceuticals.

Explore the full profile